Research ArticleArticle
Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators
Daniel E. O’Brien, Douglas M. Shaw, Hyekyung P. Cho, Alan J. Cross, Steven S. Wesolowski, Andrew S. Felts, Jonas Bergare, Charles S. Elmore, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology May 2018, 93 (5) 526-540; DOI: https://doi.org/10.1124/mol.117.110114
Daniel E. O’Brien
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Douglas M. Shaw
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Hyekyung P. Cho
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Alan J. Cross
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Steven S. Wesolowski
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Andrew S. Felts
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Jonas Bergare
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Charles S. Elmore
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Craig W. Lindsley
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
Colleen M. Niswender
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
P. Jeffrey Conn
Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery (D.E.O., D.M.S., H.P.C., A.S.F., C.W.L, C.M.N., P.J.C.), Vanderbilt Brain Institute (P.J.C.), and Vanderbilt Kennedy Center (C.M.N., P.J.C.), Vanderbilt University, Nashville, Tennessee; AstraZeneca Neuroscience Innovative Medicines, AstraZeneca, Cambridge, Massachusetts (A.J.C., S.S.W.); and AstraZeneca Pharmaceutical Sciences, AstraZeneca, Mölndal, Sweden (J.B., C.S.E.)
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
mGlu2 Allosteric Modulator Pharmacology and Binding Sites
Daniel E. O’Brien, Douglas M. Shaw, Hyekyung P. Cho, Alan J. Cross, Steven S. Wesolowski, Andrew S. Felts, Jonas Bergare, Charles S. Elmore, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology May 1, 2018, 93 (5) 526-540; DOI: https://doi.org/10.1124/mol.117.110114
Research ArticleArticle
mGlu2 Allosteric Modulator Pharmacology and Binding Sites
Daniel E. O’Brien, Douglas M. Shaw, Hyekyung P. Cho, Alan J. Cross, Steven S. Wesolowski, Andrew S. Felts, Jonas Bergare, Charles S. Elmore, Craig W. Lindsley, Colleen M. Niswender and P. Jeffrey Conn
Molecular Pharmacology May 1, 2018, 93 (5) 526-540; DOI: https://doi.org/10.1124/mol.117.110114
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement